Medivation Articles
Positive CHMP recommendations for Astellas Xtandi, Roche's Erivedge, as well MACI, Nuedexta and Spedra
28 April 2013
BioTrends views Xeljanz and Zytiga prescribing in USA
26 March 2013
New drug options for advanced prostate cancer
13 December 2012
More highlights from ESMO Congress
2 October 2012
Medivation and Astellas debut Xtandi in USA
14 September 2012
FDA backs Medivation and Astellas' prostate cancer drug Xtandi
3 September 2012
Pfizer, Medivation finally pull plug on Dimebon
18 January 2012
Strong data from MDV3100 prostate cancer trial lead Medivation and Astellas to stop study early
4 November 2011
More highlights from ASCO
7 June 2011
Astellas and Medivation see strong Ph I/II data on prostate cancer drug candidate MDV3100
16 April 2010
Showing 1-20 of 20 articles
- 1
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
